Zentalis Pharmaceuticals (ZNTL) said late Monday it closed a public offering of nearly 26.5 million common shares at $3.50 apiece for gross proceeds of $92.6 million.
The offering comprised close to 3.5 million shares issued upon the full exercise of an overallotment option by the underwriters, according to a statement.
Net proceeds will be used to fund clinical trials, regulatory filings, manufacturing, pre-commercial activities, and other general corporate purposes, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.